Skip to main content

Prior Authorization Policies for Pediatric ADHD Medication Prescriptions

We're currently migrating this dataset. To interact with these data, visit our Legacy Site.

According to the Centers for Disease Control and Prevention, more than 6.4 million US children aged 4-17 years have had attention-deficit/hyperactivity disorder (ADHD) diagnosed. The percentage of US children diagnosed with ADHD has increased by 3% to 5% per year since the 1990s. Relatedly, the percentage of children in this age group taking ADHD medication also has increased by about 7% per year from 2007-2008 to 2011-2012. Some state Medicaid programs have implemented policies to manage the use of ADHD medications and guide physicians toward best practices for ADHD treatment in children. These policies include prescription medication prior authorization requirements that restrict approvals to patients above a certain age, or require additional provider involvement before approval for payment is granted.

This dataset examines features of state Medicaid prior authorization policies that pertain to pediatric ADHD medication treatment, including applicable ages, medication types, and criteria for approval.

 

Dataset Details Supporting Documents
Created by Center for Public Health Law Research and CDC Staff Data
Valid through November 1, 2015 Codebook
Jurisdictions: 50 U.S. States and the District of Columbia Protocol